Chronic myelomonocytic leukemia (CMML) is a rare hematopoeitic malignancy characterized by dysplasia, cytopenias, a propensity to transform to Acute Myeloid Leukemia (AML) and a characteristic monocytosis that defines this entity. In the past, CMML was grouped together with the Myelodysplasitc Syndromes (MDS) but its clinical and genetic behavior is now known to be distinctly different from MDS.
As a result, this disease is now grouped in a separate MDS/MPN category by WHO. Our research interests focus on understanding the molecular and genetic pathway of chronic myelomonocytic leukemia to better design targeted agents for study in the clinic. Our previous efforts have identified the GM-CSF signaling cascade as a target for CMML therapeutics and current efforts are underway to test this in the clinic. Future work will focus on uncovering new targets for CMML specific therapies.